IMNM holder plans sale of 108,504 common shares

IMNM shareholder ABHMC II LLC, through Merrill Lynch, plans to sell 108,504 shares of common stock on or after August 6, 2026 on Nasdaq.

Rhea-AI Filing Summary

IMNM shareholder ABHMC II LLC, through Merrill Lynch, plans to sell 108,504 shares of common stock on or after August 6, 2026 on Nasdaq. The shares were acquired from the issuer in a private placement on October 3, 2023 for cash. The issuer reports 113,250,394 shares outstanding of this class.

Over the past three months, ABHMC II LLC has sold multiple IMNM common stock blocks, including 100,000 shares on June 30, 2026, 100,000 shares on July 2, 2026, and additional smaller trades through July 7, 2026. ARSENAL BRIDGE VENTURE II-B LLC also sold 1,050 shares on June 30, 2026.

Key Figures

Planned shares to be sold: 108,504 shares Aggregate value of planned sale: $2,769,022.08 Shares outstanding: 113,250,394 shares +5 more

8 metrics

Planned shares to be sold 108,504 shares Common stock to be sold on or after August 6, 2026

Aggregate value of planned sale $2,769,022.08 Value associated with 108,504 common shares

Shares outstanding 113,250,394 shares Common stock of this class outstanding

ABHMC sale 1 100,000 shares for 2,112,450 Common stock sold on June 30, 2026

ABHMC sale 2 100,000 shares for 2,258,949 Common stock sold on July 2, 2026

ABHMC sale 3 83,094 shares for 2,003,222.92 Common stock sold on July 6, 2026

ABHMC sale 4 16,906 shares for 409,125.01 Common stock sold on July 7, 2026

ARSENAL sale 1,050 shares for 22,180.72 Common stock sold on June 30, 2026

Key Terms

Form 144, Private Placement, Securities Sold During The Past 3 Months

3 terms

Form 144 regulatory

"144: Securities Information Common | Merrill Lynch..."

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Private Placement financial

"Common | 10/03/2023 | Private Placement | Issuer |"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

Securities Sold During The Past 3 Months regulatory

"144: Securities Sold During The Past 3 Months ABHMC II LLC..."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the IMNM Form 144 indicate about upcoming stock sales?

The Form 144 shows a plan to sell 108,504 IMNM common shares through Merrill Lynch on or after August 6, 2026 on Nasdaq. These shares were originally acquired in a private placement on October 3, 2023 for cash.

How many IMNM shares are outstanding according to this Form 144?

The document lists 113,250,394 IMNM common shares outstanding for the class involved. This figure provides context for the planned sale of 108,504 shares, which represents only a small portion of the total outstanding stock.

Who is selling IMNM shares and through which broker?

The planned sale of 108,504 IMNM shares is by ABHMC II LLC, using Merrill Lynch at 555 California Street, San Francisco, as the broker. Trades are expected to occur on the Nasdaq market.

When and how did the seller acquire the IMNM shares being registered?

The 108,504 IMNM shares were acquired on October 3, 2023 in a private placement directly from the issuer for cash. This acquisition method is disclosed as part of the Form 144 securities information.

What IMNM stock sales occurred in the last three months before this Form 144?

ABHMC II LLC sold 100,000 IMNM shares on June 30, 2026, another 100,000 shares on July 2, 2026, plus 83,094 and 16,906 shares on early July 2026. ARSENAL BRIDGE VENTURE II-B LLC sold 1,050 shares on June 30, 2026.

What is the approximate market value of the IMNM shares planned for sale?

The planned sale of 108,504 IMNM common shares is associated with an aggregate value of $2,769,022.08 in the document. This amount reflects the market value used for the Form 144 disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/06/2026 - 05:42 PM Accepted by SEC EDGAR 08/06/2026 - 05:41 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002129593
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Immunome, Inc.
SEC File Number	001-39580
Address of Issuer	18702 N. CREEK PARKWAY SUITE 100 BOTHEL WASHINGTON 98011
Phone	4259397410
Name of Person for Whose Account the Securities are To Be Sold	ABHMC II, LLC
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Shareholder

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 555 California Street 18th Floor San Francisco CA 94104	108504	2769022.08	113250394	08/06/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/03/2023	Private Placement	Issuer			108504	10/03/2023	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
ABHMC II LLC 4305 AVENUE D AUSTIN TX 78751	Common	06/30/2026	100000	2112450
ABHMC II LLC 4305 AVENUE D AUSTIN TX 78751	Common	07/02/2026	100000	2258949
ABHMC II LLC 4305 AVENUE D AUSTIN TX 78751	Common	07/06/2026	83094	2003222.92
ABHMC II LLC 4305 AVENUE D AUSTIN TX 78751	Common	07/07/2026	16906	409125.01
ARSENAL BRIDGE VENTURE II-B LLC 4305 AVENUE D AUSTIN TX 78751	Common	06/30/2026	1050	22180.72

144: Remarks and Signature

Remarks
Date of Notice	08/06/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/31/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	James B. Graham
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)